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Background: To determine the frequency and predictive impact of ROS1 rearrangements on treatment outcomes in
never-smoking patients with lung adenocarcinoma.
Patients and methods:We concurrently analyzed ROS1 and ALK rearrangements and mutations in the epidermal
growth factor receptor (EGFR), and KRAS in 208 never smokers with lung adenocarcinoma. ROS1 and ALK
rearrangements were identiﬁed by ﬂuorescent in situ hybridization.
Results: Of 208 tumors screened, 7 (3.4%) were ROS1 rearranged, and 15 (7.2%) were ALK-rearranged. CD74-ROS1
fusions were identiﬁed in two patients using reverse transcriptase–polymerase chain reaction. The frequency of ROS1
rearrangement was 5.7% (6 of 105) among EGFR/KRAS/ALK-negative patients. Patients with ROS1 rearrangement had
a higher objective response rate (ORR; 60.0% versus 8.5%; P = 0.01) and a longer median progression-free survival
(PFS; not reached versus 3.3 months; P = 0.008) to pemetrexed than those without ROS1/ALK rearrangement. The PFS
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to EGFR-tyrosine kinase inhibitors in patients harboring ROS1 rearrangement was shorter than those without ROS1/ALK
rearrangement (2.5 versus 7.8 months; P = 0.01).
Conclusions: The frequency of ROS1 rearrangements in clinically selected patients is higher than that reported for
unselected patients, suggesting that ROS1 rearrangement is a druggable target in East-Asian never smokers with
lung adenocarcinoma. Given the different treatment outcomes to conventional therapies and availability of ROS1
inhibitors, identiﬁcation of ROS1 rearrangement can lead to successful treatment in ROS1-rearranged lung
adenocarcinomas.
Key words: lung adenocarcinoma, never smoker, outcome, ROS1
introduction
Lung cancer in never smokers (LCINS) is regarded as a
distinct disease entity with a distinct molecular
subclassiﬁcation [1]. Notably, actionable mutations in
epidermal growth factor receptor (EGFR), KRAS, and
anaplastic lymphoma kinase (ALK)-rearrangement are three
major recurrent oncogenic alterations in LCINS [1–3]. Other
genetic aberrations in LCINS include HER2 mutations and
KIB5B-RET fusion, although these mutations are known to
occur with low frequencies [4].
Recently, ROS1 rearrangement has emerged as a new
molecular subtype in non-small-cell lung cancer (NSCLC),
and now comprises a distinct molecular classiﬁcation of
NSCLC. ROS1 rearrangement in NSCLC was discovered in
2007 by Rikova, who identiﬁed two ROS1 fusion products
(SLC34A2-ROS1 and CD74-ROS1) in a cell line and a tumor
with high ROS1 phospho-peptides [5]. ROS1 rearrangements
result in the formation of fusion proteins having constitutive
tyrosine-kinase activity through the dimerization of ROS1
fusion partners which subsequently stimulates downstream
signaling, resulting in enhanced cell growth, proliferation, and
decreased apoptosis.
In an unselected NSCLC population, the frequency of ROS1
rearrangement ranged from 0.9% to 1.7% [3, 6, 7]. Recently,
Bergethon et al. [3] reported a strong association between ROS1
rearrangements and never smoking. However, because most
studies investigated predominantly smokers, the frequency of
ROS1 rearrangements in East-Asian never smokers remains
unknown. Furthermore, whether patients with ROS1-rearranged
NSCLC share similar outcomes to other genetically deﬁned
subsets, particularly in the metastatic setting, also is unknown.
Preclinical and clinical data have demonstrated that ROS1-
positive tumors are sensitive to crizotinib [3]. This indicates that
ROS1-positive NSCLC represents a novel patient subset that
may derive clinical beneﬁt from ROS1 inhibition [8].
Preliminary data from a phase I trial of crizotinib
(NCT00585195) in the ROS1-positive NSCLC expansion-cohort
demonstrated an overall response rate (ORR) of 57%. However,
the sensitivity of ROS1-positive NSCLC to cytotoxic
chemotherapy or EGFR-tyrosine kinase inhibitors (TKIs) in
patients with NSCLC with ROS1 fusions has not been evaluated.
Herein, we determined the frequency of ROS1 rearrangement
with the identiﬁcation of fusion partners in the largest-ever
cohort of East-Asian never smokers with NSCLC. We also
examined the clinicopathological characteristics and treatment
outcomes of patients with lung adenocarcinomas with ROS1
rearrangement.
materials and methods
study population and data collection
This study was conducted in a cohort of histologically conﬁrmed never
smokers with lung adenocarcinoma at Severance Hospital, Seoul, Korea,
between January 2005 and February 2012. The criteria used for patient
selection included: (i) availability of tumor tissue, (ii) smoking-history,
(iii) genetic data (EGFR and KRASmutation and ALK rearrangement), and
(iv) survival data. Tumor histology was classiﬁed using the 2011
International Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society classiﬁcation of Lung
Adenocarcinoma. Never smokers were deﬁned as those with a lifetime
smoking dose of <100 cigarettes. A total of 208 consecutive never smokers
with histologically conﬁrmed lung adenocarcinoma were enrolled.
A predesigned data collection format was used to review the patients’
medical records for evaluation of clinicopathological characteristics and
survival outcomes. For patients with metastatic disease, we examined
treatment regimens, ORR, and survival outcomes. Clinical responses were
classiﬁed using the Response Evaluation Criteria in Solid Tumor (RECIST
version 1.1). Progression-free survival (PFS) was measured from the ﬁrst day
of treatment to tumor progression or death, while overall survival (OS) was
measured from the date of diagnosis of metastatic disease until the date of
death. Patients were censored on 26 October 2012, if alive and progression
free. Patients without a known date of death were censored at the time of last
follow-up. This study was approved by the Institutional Review Board of
Severance Hospital. All patients signed a written informed consent for
genetic analysis.
ROS1 rearrangements
To identify ROS1 rearrangements, ﬂuorescent in situ hybridization (FISH)
assays were carried out on formalin-ﬁxed and parafﬁn-embedded (FFPE)
tumors by using a break-apart probe to ROS1 (Break-Apart Rearrangement
Probe; Abbott Molecular®) according to manufacturer’s instructions.
FISH-analyses were interpreted by two experienced evaluators (HSS and
JKP) who were blinded to the clinical and genetic data. At least 100 nuclei
per case were evaluated. FISH positivity for ROS1 rearrangement was
deﬁned as >15% of tumor cells with a split signal. FISH-positive tumors
were conﬁrmed by immunohistochemistry (IHC) using antibody against
ROS1. FFPE tissues were sectioned at a thickness of 4 μm and stained using
Ventana automated immunostainner BenchMark XT. The slides were dried
at 60°C for 1 h and deparafﬁnized using EZ Prep at 75°C for 4 min. Cell
conditioning was carried out using CC1 solution at 100°C for 64 min. ROS1
antibody (rabbit monoclonal, clone D4D6, Cell Signaling Technology) was
diluted to 1:50, treated, and incubated at 37°C for 32 min. Signals were
detected using OptiView DAB IHC Detection Kit (Ventana Medical
Systems). Counterstaining was carried out with Hematoxylin I for 4 min at
room temperature.
To identify the known fusion partners of ROS1, reverse transcriptase–
polymerase chain reaction (RT-PCR) was carried out using the SuperScript
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III First-Strand Synthesis System (Invitrogen) with a previously published
ROS1 primer located in exon 32, exon 34, exon 35, and exon 36 [9]. PCR
products positive for the ROS1 fusions were excised from the agarose gel,
puriﬁed (Wizard SV Gel and PCR Clean-Up Kit; Promega), and then
sequenced.
thymidylate synthase IHC and scoring
Thymidylate synthase (TS) antibody (rabbit polyclonal, clone H-265, Santa
Cruz Biotechnology) was diluted to 1:50, treated, and incubated at 37°C for
32 min. For TS, a semiquantitative scoring was used, and the results were
represented as intensity multiplied by proportion.
ALK rearrangements, EGFR, and KRASmutation
analysis
To identify ALK rearrangements, FISH studies were carried out on FFPE
tumors by using a break-apart probe to ALK (Vysis LSI ALK Dual Color,
Break-Apart Rearrangement Probe; Abbott Molecular) [2]. Nucleotide
sequencing of the kinase domain of EGFR (exons 18 to 21) and KRAS exon
2 (codons 12/13) was carried out using nested PCR-ampliﬁcation of the
individual exons [2]. Details of these methods have been described
previously [2].
cell culture and cell viability assay
The human NSCLC cell lines, A549, H460, H1299, HCC827, and H2228,
were purchased from the American Type Culture Collection and PC-9 and
H3122 were kind gifts from Drs K. Hayata (Tokyo Medical College) and
John D. Minna (University of Texas Southwestern). After cells were
exposed to drugs for 72 h, 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) solution was added to the well. The
optical density of the MTT formazan product was read at 565 nm on a
microplate reader.
statistical analysis
Signiﬁcant differences in variables according to each genotype were
tested using the χ2 test, Fisher’s exact test, or t-test, as appropriate. The
Kaplan–Meier method was used to estimate PFS and OS, and the differences
according to genotype were compared using the log-rank test. Adjusted
hazard ratios (AHRs) for the risk of progression or death in response to
treatment according to genotype were calculated using a Cox-regression
model that included age, gender, and genetic alteration as independent
variables. All P-values were based on a two-tailed hypothesis.
results
clinicopathologic characteristics of patients with
ROS1 rearrangement
We screened ROS1 rearrangements in 208 never smokers with
lung adenocarcinoma. ROS1-positive lung adenocarcinoma was
detected in 7 of 208 samples (3.4%). There was no signiﬁcant
difference in baseline characteristics between ROS1-positive and
-negative cases. The median age of ROS1 positive was
numerically younger than that of ROS1 negative without
statistical signiﬁcance, probably due to the fact that the
majorities in our study were elderly women (Table 1). Although
ROS1 rearrangement was mutually exclusive from ALK
rearrangement and KRASmutation, one of seven ROS1-positive
Table 1. Demographic and clinical characteristics of patients with ROS1-positive lung adenocarcinoma











Age (years) 0.80 0.95
Median 58 55 58 58
Range 30–78 30–68 34–78 33–77
Sex 0.69 0.58
Male 32 (15.4) 1 (14.3) 2 (13.3) 29 (15.6)
Female 176 (84.6) 6 (85.7) 13 (86.7) 157 (84.4)
Stagea 0.82 0.92
I 41 (19.7) 2 (28.6) 3 (20.0) 36 (19.4)
II 26 (12.5) 0 (0) 3 (20.0) 23 (12.4)
IIIA 38 (18.3) 1 (14.3) 3 (20.0) 34 (18.3)
IIIB 17 (8.2) 1 (14.3) 1 (6.7) 15 (8.1)
IV 86 (41.3) 3 (42.9) 5 (33.3) 78 (41.9)
Type of mutation
EGFR 83 (39.9) 1 (14.3) – 82 (44.1) 0.24 <0.001
Exon19 deletion 51 (24.5) – – 51 (27.4)
Exon21 L858R 28 (13.5) 1 (14.3) – 27(14.5)
Othersb 4 (1.9) – – 4 (2.2)
KRAS 5 (2.3) – – 5 (2.6) 0.83 0.68
Gly12Asp (GGT→GAT) 3 (1.4) – – 3 (1.6)
Gly12Ser (GGT→AGT) 2 (0.9) – – 2 (1.0)
aClinical stage at the time of initial diagnosis was determined according to the 6th American Joint Commission on Cancer guideline.
bThese four patients had double mutations in exon 19 (del 2235–2249)/exon 20 (T790M), exon 20 (T790M)/exon 21 (L858R), exon 20 (A871G)/exon 21
(L858R), and exon 21 (L858R/Leu833Val).
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patients had a concurrent EGFRmutation (exon21 L858R)
(supplementary Table S1, available at Annals of Oncology
online). The frequency of ROS1 rearrangement was 5.7% (6/
105) among EGFR/KRAS/ALK-negative patients. When we
carried out IHC on the FISH-positive tumors, all ROS1-FISH-
positive cases also were ROS1 positive in IHC (supplementary
Figure S1, available at Annals of Oncology online).
identiﬁcation of ROS1 fusion partners by RT-PCR
We found CD74-ROS1 fusions in two patients by RT-PCR and
sequencing (supplementary Figure S2, available at Annals of
Oncology online). No fusion partner was identiﬁed in the
remaining ﬁve tumors. The latest update of ROS1 fusion
partners including our results is illustrated in supplementary
Figure S3, available at Annals of Oncology online.
treatment outcomes of ROS1-rearranged lung
adenocarcinoma
Table 2 summarized the treatment outcomes in 162 metastatic
lung adenocarcinoma patients who received palliative
chemotherapy. Single agent pemetrexed either in the second- or
third-line setting was administered in a total of 82 patients
(50.6%). The ORR to pemetrexed in ROS1-positive patients was
higher than that inWT/WT (60.0% versus 8.5%; P = 0.01).
EGFR-TKIs were administered in 120 patients as a second or
third line. None had received ALK inhibitors previously. None
of the patients with ROS1 rearrangement (n = 3) had a clinical
response to EGFR-TKIs. Similarly, there was no responder to
EGFR-TKIs among patients with ALK rearrangement. The ORR
to EGFR-TKIs in patients with ROS1 rearrangement was
numerically lower than that inWT/WT, although not
statistically signiﬁcant (0% versus 25.7%). These results might
be due to a small sample size. With a median follow-up
duration of 29.6 months, 82 (39.4%) of 208 patients were still
alive at the time of analysis.
ROS1 rearrangement conferred a signiﬁcantly longer median
PFS with pemetrexed thanWT/WT (not reached versus 3.3
months forWT/WT; P = 0.008; Figure 1B). However, patients
with ROS1 rearrangement showed signiﬁcantly shorter median
PFS to EGFR-TKIs thanWT/WT (2.5 versus 7.8 months in
WT/WT; P = 0.01; Figure 1C). Additionally, we compared the
treatment outcome of EGFR-TKI in ROS1-positive patients with
that of triple-negative for EGFR/ALK/ROS1. There was no
difference in treatment outcome of EGFR-TKI in terms of ORR
and PFS.
In a Cox-regression model adjusted for age, gender, EGFR
mutation, and ALK rearrangement, the AHR for the risk of
disease progression to pemetrexed was 0.09 (P = 0.02) for
patients with ROS1 rearrangement. This suggests that ROS1
Table 2. Summary of treatment outcomes by genotype in metastatic lung adenocarcinoma patients who received palliative chemotherapy












Platinum-based CT 133 (82.1) 5 (100) 9 (69.2) 119 (82.6) 0.64 0.48
Pemetrexed 82 (50.6) 5 (100) 6 (46.2) 71 (49.3) 0.11 0.58
EGFR-TKI 120 (74.1) 3 (60.0) 8 (61.5) 109 (75.7) 0.22 0.52
Line of platinum-based CT
First line 133 (100%) 5 (100) 9 (100) 119(100) – –
Line of pemetrexed 0.96 0.89
First line 0 (0) 0 (0) 0 (0) 0 (0)
Second line 33 (40.2) 2 (40.0) 2 (33.3) 29 (40.8)
Third line and more over 49 (59.8) 3 (60.0) 4 (66.7) 42 (59.2)
Line of EGFR-TKI 0.67 0.17
First line 4 (3.3) 0 (0) 1 (12.5) 3 (2.8)
Second line 96 (80.0) 3 (100) 7 (87.5) 86 (78.9)
Third line 20 (16.7) 0 (0) 0 (0) 20 (18.3)
Best response to platinum-based CT
ORR 29 (21.8) 2 (40.0) 0 (0) 27 (22.7) 0.33 0.20
DCR 107 (80.5) 5 (100) 6 (66.7) 96 (80.7) 0.58 0.39
Best response to pemetrexed
ORR 11 (13.4) 3 (60.0) 2 (33.3) 6 (8.5) 0.01 0.12
DCR 54 (65.9) 5 (100) 4 (66.7) 46 (64.8) 0.16 0.62
Best response to EGFR-TKIsb
ORR 28 (23.5) 0 (0) 0 (0) 28 (25.7) 0.56 0.20
DCR 80 (67.2) 0 (0) 1 (12.5) 79 (72.5) 0.08 0.001
aThe one patient had ROS1 rearrangement plus following EGFRmutations (exon21 L858R).
bThe patient with concurrent ROS1 rearrangement and EGFRmutation was not included in the response analysis in EGFR-TKI.
WT, wild type; CT, chemotherapy; EGFR, epidermal growth factor receptor; NS, not signiﬁcant; TKIs, tyrosine kinase inhibitors; PR, partial response;
SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate (CR + PR + SD).
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rearrangement is a strong predictive factor for a longer median
PFS to pemetrexed. The AHR for the risk of progression to the
EGFR-TKIs was 2.40 (P = 0.14) for ROS1 rearrangement, 0.56
(P = 0.007) for EGFRmutation, and 2.70 (P = 0.02) for ALK
rearrangement (supplementary Table S2, available at Annals of
Oncology online). These results indicate that EGFRmutations
are a strong positive predictive factor for a longer median PFS
after EGFR-TKI, whereas ALK rearrangements have a negative
predictive impact. Furthermore, ROS1 rearrangement may be a
negative predictor for a longer PFS to EGFR-TKI, although
statistical signiﬁcance was not reached likely due to sample size
limitation.
pemetrexed inhibits ROS1 activity and cell growth
in vitro
We carried out a cell viability assay in various NSCLC cell lines
using pemetrexed, geﬁtinib, crizotinib, and TAE684.
Pemetrexed is highly sensitive, but geﬁtinib is resistant to ROS1-
rearranged HCC78 and ALK-rearranged H3122. As the TS
expression has been reported to be associated with the
sensitivity to pemetrexed [10], we examined TS level in various
cell lines. TS expression was rarely detected in pemetrexed-
sensitive HCC78, H3122, PC9, and HCC827, while pemetrexed-
resistant H358 and H1299 showed high TS expression
(Figure 2). As shown in supplementary Figure S4, available at
Annals of Oncology online, patients with ROS1 or ALK
rearrangement tend to show lower TS scoring than those with
WT/WT.
discussion
We reported the frequency and treatment outcomes of ROS1-
rearranged NSCLC from East-Asian never smokers. The
enrichment of never smokers resulted in a higher frequency
(3.4%) of ROS1 rearrangement compared with that in
unselected populations (0.9%∼1.7%), further supporting that
ROS1 rearrangements, together with EGFRmutations and ALK
rearrangements, are the genetic alterations that are speciﬁc
for LCINS [2, 3]. ROS1 rearrangements were mutually exclusive
with three major recurrent oncogenic mutations in LCINS, such
as EGFR or KRASmutation or ALK rearrangement, comprising
a unique and nonoverlapping molecular subset of LCINS. The
treatment outcome of ROS1-rearranged NSCLC was distinct
from that ofWT/WT tumors, but similar to that of ALK-
rearranged NSCLC, which may suggest the biological similarity
of ROS1- and ALK-rearranged NSCLC. To our knowledge, this
is the ﬁrst and the most comprehensive study reporting the
frequency, clinicopathologic features, and treatment response at
the same time in ROS1-rearranged lung adenocarcinomas from
East-Asian never smokers.
Several studies have examined the frequency of ROS1
rearrangement in NSCLC. Bergethon et al. [3] reported that
ROS1 rearrangements were enriched in Asians and never
smokers. However, in the other studies that primarily involved
Asian patients and/or never smokers, the frequency of ROS1
rearrangement has been reported to range from 0.9% to 1.6%,
which was similar to that reported in unselected population [6,
7, 11]. Potential explanations for the lower frequency of ROS1
rearrangement in these studies may exist. In a report by Li et al.,
the authors examined ROS1 rearrangement by RT-PCR which
limited the detection of fusion partners to CD74 and SLC34A2
only. Rimkunas et al. [7] screened ROS1 rearrangements using
IHC assay from Chinese patients with unknown smoking-
status. A study by Takeuchi et al. [6] investigated predominantly
smokers. Recently, Cai et al. [12] reported that the ROS1
rearrangements were found in ∼2.0% of Chinese patients and
had worse survival outcome compared with ROS1 negative.
Unfortunately, most of the above studies did not concurrently
analyze EGFR and KRASmutations and ALK rearrangements,
the three most frequently identiﬁed and clinically relevant
genetic alterations in LCINS.
With the screening for ROS1 rearrangements by using
FISH and the enrichment of never smokers, we
Figure 1. Progression-free survival (PFS) according to ROS1 rearrangement in lung adenocarcinoma patients who received palliative chemotherapy. (A) PFS
in patients treated with platinum-based chemotherapy: patients with ROS1 rearrangement (n = 5), ALK rearrangement (n = 9), andWT/WT (n = 119) (B) PFS
in patients treated with pemetrexed chemotherapy: patients with ROS1 rearrangement (n = 5), ALK rearrangement (n = 6), andWT/WT (n = 71). (C) PFS in
patients treated with EGFR-tyrosine kinase inhibitors (TKIs) treatment: patients with ROS1 rearrangement (n = 3), ALK rearrangement (n = 8), andWT/WT
(n = 109).
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demonstrated that the frequency of ROS1 rearrangements
was 3.4%, suggesting that ROS1 rearrangement is a
druggable target in East-Asian never smokers with lung
adenocarcinoma. Notably, the frequency of ROS1
rearrangements was 5.7% among EGFR/KRAS/ALK-negative
patients. Taken together, our data suggest that ROS1
rearrangements were associated with never-smoking status,
especially in patients who are negative for three major
oncogenic mutations most frequently identiﬁed in
LCINS [2].
In our study, ROS1 rearrangement was associated with a
different response and survival outcome after EGFR-TKIs
and/or pemetrexed treatment. Patients with ALK and ROS1
rearrangement had poorer outcomes after EGFR-TKIs.
Intriguingly, we noted that patients with ROS1
rearrangement had a signiﬁcantly better ORR and median
PFS on pemetrexed than those without ROS1
rearrangement. Similarly, previous studies have shown that
ALK-positive patients had signiﬁcantly longer PFS on
pemetrexed compared with ALK negative [13]. It was
suggested that ALK-positive tumors had low level of TS,
leading to high susceptibility to pemetrexed. Our study
demonstrated that patients with ALK rearrangement tend to
show favorable PFS to pemetrexed compared with WT/WT
even with no statistical signiﬁcance. The reason for
discrepancies with previous data could be explained by
following limitations of our study; retrospective data, small
number of ALK positive, and treatment of pemetrexed as
third line and more over. We also discovered low TS level
and the highest sensitivity to pemetrexed in ROS1-positive
HCC78, compared with other cell lines. The similar clinical
characteristics might be related with the structural and
functional homology between two genotypes. However, the
underlying mechanism for the favorable response to
pemetrexed is still unclear. Since this was a retrospective
study and that the number of ROS1 positive was small, we
think that the sensitivity to pemetrexed of ROS1-positive
patients should be cautiously interpreted.
To date, eight ROS1 fusion genes including CD74-ROS1,
SLC34A2-ROS1, SDC4-ROS1, EZR-ROS1, FIG-ROS1, TPM3-
ROS1, LRIG3-ROS1, and KDELR2-ROS1 have been identiﬁed.
Among them, CD74-ROS1 is the most common fusion partner
in NSCLC [3, 5–7, 9, 11, 12, 14–16]. In our study, CD74 was
found as a fusion partner in two patients. No fusion partner was
identiﬁed in the other ﬁve cases, possibly due to insufﬁcient
tissue sample or poor quality of extracted RNA in FFPE.
Regarding the ALK result in our study, the 7.2% prevalence and
mutual exclusiveness with EGFR and/or KRASmutation is very
similar with recent data [17, 18].
In conclusion, ∼3.4% of lung adenocarcinoma from East-
Asian never smokers harbors ROS1 rearrangement. Because of
the different treatment outcomes and the existence of ROS1
inhibitors in this molecular subset, the identiﬁcation of ROS1
rearrangement before the initiation of treatment should be a
routine practice in personalized therapy.
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